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ABSTRACT: Whooping cough causes significant morbidity and mortality, especially in early 
infancy. Although an effective vaccine exists, vaccine uptake in Malta was previously disappointing 
due to the general public's and the medical community's doubts regarding vaccine efficacy and 
safety. The aim of this study was to review population-based studies which have analysed the 
potential short and long term neurological sequelae following pertussis and pertussis vaccination, to 
describe vaccine uptake globally and in Malta over the past 15 years, and to analyse the effect of 
vaccine uptake on pertussis epidemics in Malta. This study found that pertussis vaccine uptake has 
only become satisfactory in recent years, with a resulting attenuation in the most recent pertussis 
outbreak. Uptake has increased progressively all over the world, and no study has ever 
incriminated pertussis vaccination as a cause of permanent neurological disability, both locally and 
abroad. This should encourage the present continuing trend of pertussis uptake. 
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Introduction Methods 
Whooping cough is a bacterial infection caused by Medline was searched using the keywords 'whooping 
Bordatella pertussis, which can cause significant cough' and 'encephalopathy'. Population-based studies 
morbidity and mortality . Infants between 1 and 2 months which analysed cases of encephalopathy occurring in 
of age are at highest risk for pertussis, along with the association with pertussis or pertussis vaccination were 
highest rates of hospitalisation (82%), pneumonia (25%), identified. For the estimation of pertussis vaccine uptake, 
seizures (2-4%), encephalopathy (0.3-1%), and death since the pertussis vaccine is almost invariably given as 
(0.2-1 %)1,2. a combined DTP vaccine, the statistics for the combined 
Neurological symptoms may be caused by endotoxin vaccine were used. Pertussis vaccine uptake was defined 
release due to bacterial lysis, asphyxia, CO2 retention, as percentage of infants surviving the first year of life, 
loss of cerebral vascular autoregulation, or a who have received three doses of combined vaccine 
combination of these factors2. Seizures, encephalopathy (DTP3). Unless stated otherwise, DTPIDTP3 refer to the 
and other neurological manifestations are complications whole-cell pertussis vaccine, which does not include 
that also occur in adults3. vaccination with acellular preparations of pertussis 
A widespread impression that Diphtheria-Tetanus­ vaccine. 
Pertussis (DTP) vaccine can cause brain damage was DTP3 data for Malta was obtained from statIstIcs 
initially based on historical precedent. Smallpox and maintained by the Department of Primary Health Care, 
rabies vaccines were recognised as occasionally causing while DTP3 statistics for individual countries - such as 
devastating neurological complications, and in the minds the United Kingdom - and for global regions, were 
of the lay public and the medical community, this obtained from WorId Health Organisation 
analogy was extended to pertussis. In addition, anecdotal publications5,6 . 
case reports of a syndrome of pertussis vaccine Annual Maltese figures for w(lOoping cough were 
encephalopathy began to be reported over 60 years obtained from 1980 to 19965. Annual population 
ag04.This study reviews the literature regarding pertussis estimates? were then used to calculate Maltese pertussis 
and pertussis vaccine related complications, with rates per 100,000 population. 
emphasis on neurological complications, reviews the Excel was used for data entry and for charting. SPSS 
literature regarding pertussis vaccine uptake, and was used for non-parametric correlations of vaccine 
compares this with the situation in Malta. uptake and pertussis rates with time (Kendall's t test). A 
p value of 0.05 was taken to represent a statistically 
significant result. 
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Table 1 - Correlation of percentage uptake of 3 doses of 
combined diphtheria, tetanus, pertussis 
and polio vaccine by 1 year of age with time 
-
Results 
Globally 
DTP3 uptake has increased significantly in all of the 
World Health Organisation regions (p:5 0.001 - Table 1). 
WHO global statistics show DTP3 uptake has more than 
doubled in the past 15 years, from approximately 35% to 
almost 80% (Figure 1). Analysis of DTP3 for developed 
regions shows >80% uptake for the UK and America 
(Figure 1). Although uptake is not as high indeveloping 
regions, the trend is persistently upwards (Figure 2). 
Locally 
DTP3 uptake in Malta has increased significantly 
(Table 1), climbing rapidly since the mid-1990s to reach 
the 80% level (Figure 3). Pertussis outbreaks in Malta 
show classical 4-yearly peaks (Figure 3). The last 
classical outbreak was in 1991, and the effect of 
DTP3>40% is instantly discernible, with attenuation of 
the next expected outbreak in 1995. There have been no 
cases of permanent neurological sequelae definitively 
attributable to DTP vaccination. 
Discussion 
Historical background to DTP vaccination 
The development and extensive uptake of an effective 
DTP vaccine (taken in three doses in infancy) in the 
United States in the 1930s led to a decline in the 
incidence of pertussis in this region, and instilled 
confidence in a vaccination programme which continues 
to this day. This contrasts with the turbulent history of 
pertussis vaccination in the United Kingdom, where 
doubts as to the efficacy of pertussis vaccines delayed 
their active national promotion until the late 1950s, after 
which various reports reinforced the . medical 
community's and the general public's doubts regarding 
DTP vaccine efficacy and safety4. 
In 1974, the media were deeply embroiled in the issue 
when the National Hospital for Sick Children case series 
of neurological events was aired in a television 
documentary. This study allegedly identified patients 
with neurological sequelae which had occurred after 
DTP vaccination. 
The Courts were also involved when a claim for 
damages in the High Court of Justice in London in 1989 
(Loveday vs Renton and The Wellcome Foundation) 
dealt with the issue of whether pertussis vaccine could 
cause permanent neurological sequelae. The foundation 
of this claim was the apparent clustering of neurological 
disorders within the fIrst 24 to 48 hours after DTP 
vaccination. One of the findings of the National 
Childhood Encephalopathy Study (NCES) which came 
to light in court, was that permanent brain damage did 
not occur within 48 hours of DTP vaccination in any 
child in England, Scotland and Wales from mid-1976 to 
mid-1979, when two million doses of vaccine had been 
given, although an excess of febrile convulsions in the 
first 24 hours was noted. All temporally associated cases 
with permanent sequelae had either viral encephalitis or 
Reye's syndrome, and no cases were unexplained8. The 
High Court's judgement was that there was no evidence 
that DTP vaccination causes permanent neurological 
sequelaeB• 
A reduction of DTP uptake, or even discontinuation, 
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Fig. 1 - Percentage uptake of 3 doses of combined 
diphtheria, tetanus, pertussis and polio 
vaccine by 1 year of age in WHO developed 
regions (UK and America), the UK and globally 
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was also observed in other countries, including Sweden. 
Japan, the USSR, Ireland, Italy, the former West 
Germany and Australia, leading to a sharp rise in the 
number of reported cases of pertussis during epidemics9• 
On the other hand, countries which maintained a high or 
compulsory uptake of DTP, including Hungary, the 
former East Germany, Poland and the United States, had 
reported rates of pertussis which were 10-100 times 
lower9. In the United Kingdom, confidence in DTP was 
enhanced by introducing the vaccine at an earlier age, 
which is associated with a decreased incidence of 
reactions. This practice was also followed in Malta. 
Known complications ofDTP vaccination 
DTP vaccination may cause various reactions within 
48 hours of administration, which include hypotonic­
hyporesponsive episodes, seizures and fever ~ 40.5°CiO. 
Children with seizures tend to have a high rate of 
personal and family histories of seizures, and fever 
occurring in association with DTP vaccination (~ 
380C)10. Persistent crying (~ 3 hours) is generally noted 
in association with painful local reactions~o. A rare 
association has also been described between DTP 
vaccination and anaphylaxis 11. 
Large, population-based studies have concluded that 
combined DTP vaccine may, on rare occasions be 
associated with the development of severe acute 
neurological illnesses, with only the potential for severe, 
long-term sequelae. Some of the cases of severe acute 
neurological illnesses observed may have occurred due 
to chance alone, or may have had other causes. It is 
impossible to determine retrospectively the role of the 
pertussis component of the vaccine in these case.s, as a 
primary or secondary factor I2-15 . 
It is important to emphasise that no population studies 
have ever implicated DTP vaccination as a cause of 
permanent neurological sequelae, and this must be 
weighed against the known morbidity and mortality that 
occurs in assoclatlOn with pertussis itself. DTP 
vaccination is given at the age of emergence of primary 
neurologic disease, and a temporal link between DTP 
vaccination and the recognition of such problems may be 
established in the minds of parents and doctors alike, and 
a causal link inferred. 
Also, no evidence has been found to link DTP 
vaccination with infantile spasms, hypsarrhythmia, 
Reye's syndrome, aseptic meningitis, Guillain-Barre 
syndrome, peripheral mononeuropathy, or indeed, any 
form of chronic neurologic damage including learning 
disabilities and attention-deficit disorder I I. Furthermore. 
no link has been found with sudden infant death 
syndrome, erythema multiforme or other rashes. 
haemolytic anaemia, juvenile diabetes, or 
thrombocytopenia11. 
The following are the modem contraindications to 
pertussis vaccination 16: 
Severe local reactions: 
• More than half the limb involved. 
Severe generalised reactions: 
• Marked febrile reactions (> 39.5 0C) within 48 hours 
of vaccination 
• Allergic reactions: Anaphylaxis, bronchospasm or 
laryngeal oedema 
• Generalised collapse 
• Prolonged unresponsiveness 
• Prolonged screaming (> 4 hours) 
• Convulsions or encephalopathy within 48 hours of 
vaccination 
Failure to vaccinate must be weighed against the 
known morbidity and mortality of pertussis itself. 
Vaccinators should be strongly discouraged from the 
inappropriate deferral of pertussis immunisation due to 
mild illness, or the omission of vaccine because of non­
existent contraindications. This is especi'ally important in 
children who have underlying conditions which may 
place them at greater risk of acquiring pertussis infection 
and its potential complications. 
Locally 
Malta has followed the rest of the world in increasing 
the uptake of pertussis vaccination over the past decade. 
The effect of a high herd immunity limiting the spread of 
pertussis, which has been brought about by a high uptake 
of DTP3, is readily apparent (Figure 3), with a marked 
drop in the number of reported cases in the most recent 
pertussis outbreak, when compared to previous 
outbreaks. Increased uptake is attributed to a number of 
factors including the effective allaying of misguided 
public fears by the Department of Primary Health Care 
with regard to vaccine safety, and an increasing number 
of local paediatricians who follow logical guidelines in 
pertussis vaccination practice. A further stimulus to 
vaccination would also include morbidity and mortaIity 
observed locally 17. 
Conventional DTP consists of killed whole organisms 
(whole-cell vaccine). A new acellular pertussis vaccine, 
containing partially purified protein antigens, 
fIlamentous hemagglutinin, and lymphocytosis­
promoting factor hemagglutinin has been developed for 
use, and was initially tested in Japan in a randomised 
double-blind trial, vaccinating children at the appropriate 
time. Acellular pertussis vaccine was found to be 
significantly less reactogenic for fever, pain, fretfulness 
and local reactions at the vaccine administration site 18 . 
The role of this vaccine is uncertain, and the World 
Health Organisation continues to recommend use of 
whole-cell vaccine. 
Conclusions 
Pertussis is a dangerous and potentially lethal illness, 
immunisation is effective in protecting against the 
disease, and should therefore be strongly encouraged. 
There is no proof that the incidence of complications 
from DTP whole-cell vaccination of children with 
seizure disorders or other pre-existing stable neurologic 
abnormalities is higher. and therefore the balance of 
possible risk against known benefits of pertussis 
immunisation supports continued use of the DTP 
vaccination even under such circumstances. 
There is overwhelming evidence to show that the 
occasional neurological illness following whole-cell 
DTP vaccination has a temporal, rather than a causal 
relationship. as the vaccine is given at the age of 
emergence or recognition of primary neurologic disease. 
-----
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